Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0G0YZ
|
||||
| Former ID |
DIB018048
|
||||
| Drug Name |
UK-356202
|
||||
| Synonyms |
compound 13j [PMID: 15149680]; UK-356,202
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Myocardial hypertrophy [ICD10:I51.7] | Clinical trial | [527081] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C17H13ClN4O2
|
||||
| InChI |
InChI=1S/C17H13ClN4O2/c18-14-8-21-15(22-17(19)20)13-7-10(4-5-12(13)14)9-2-1-3-11(6-9)16(23)24/h1-8H,(H,23,24)(H4,19,20,21,22)
|
||||
| InChIKey |
UXNWIRHZMHGOCE-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Urokinase-type plasminogen activator | Target Info | Inhibitor | [527081] | |
| NetPath Pathway | IL2 Signaling Pathway | ||||
| EGFR1 Signaling Pathway | |||||
| Pathway Interaction Database | Beta1 integrin cell surface interactions | ||||
| E2F transcription factor network | |||||
| Beta3 integrin cell surface interactions | |||||
| Osteopontin-mediated events | |||||
| Validated transcriptional targets of AP1 family members Fra1 and Fra2 | |||||
| amb2 Integrin signaling | |||||
| ATF-2 transcription factor network | |||||
| AP-1 transcription factor network | |||||
| Beta2 integrin cell surface interactions | |||||
| Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||||
| Beta5 beta6 beta7 and beta8 integrin cell surface interactions | |||||
| FGF signaling pathway | |||||
| Reactome | Dissolution of Fibrin Clot | ||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.